Pharmaceutical

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

Full ENVASARC accrual expected in Q4 and final data expected in mid-2024SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON…

12 months ago

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

- Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program for AD109, a potential new…

12 months ago

Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference

Morgan Stanley Fireside Chat Replay Now AvailableSAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the…

12 months ago

POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands

Enables the efficient expansion of surface targets for radioisotope deliveryINDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT…

12 months ago

Notice of Extraordinary General Meeting Promore Pharma AB (Publ)

STOCKHOLM, SWEDEN / ACCESSWIRE / September 18, 2023 / Promore Pharma (STO:PROMO) (FRA:8T0)Unofficial English translation for information purposes only. If…

12 months ago

AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / September 18, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), )…

12 months ago

Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC

· Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals.· Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for…

12 months ago

Mydecine Innovations Group Files Prospectus Supplement

VANCOUVER, British Columbia, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA)…

12 months ago

Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023

HILLSIDE, NJ / ACCESSWIRE / September 15, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial…

1 year ago

Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering

JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on…

1 year ago